Johnson & Johnson vs Pfizer
Two pharmaceutical giants compared on moat durability, balance-sheet strength, and margin of safety — a classic Buffett-style value pairing in healthcare.
| Metric | JNJ JNJ | Pfizer Inc. PFE |
|---|---|---|
| ValueOS Score | 63 | 79 |
| Verdict | HOLD | BUY |
| Moat | Narrow Moat | Narrow Moat |
| Margin of Safety | -19.101703825433862% | 0% |
| Intrinsic Value | $579.9B | $195.3B |
| Price | $250.61 | $24.94 |
Live scores from the latest SEC filings · refreshed daily. Open any card for the full workup.
The Takeaway
Johnson & Johnson is the more diversified, lower-risk franchise — consumer health, medtech, and pharma under one wide-moat roof with a fortress balance sheet. Pfizer's earnings are more pipeline-dependent and volatile, so its margin of safety matters more. Use the live Score, Moat, and DCF cards to see which is trading with the larger cushion today.
Frequently Asked Questions
Which has the wider moat, J&J or Pfizer?
J&J's diversification across three segments gives it a broader, more durable moat; Pfizer leans on patent-protected drugs that eventually face generic competition. The Moat cards above show the current read.
Which is cheaper right now?
Open the DCF cards above to compare intrinsic value with live price. The name with the larger positive margin of safety is cheaper on our model.
Compare any stock yourself
Run the full Buffett-style workup on either name.
Cite this page
Quoting or linking ValueOS? Copy this ready-made citation.
ValueOS Editorial Team. "Johnson & Johnson vs Pfizer." ValueOS. Accessed 2026-07-22. https://getvalueos.com/compare/jnj-vs-pfe